|Bid||22.40 x 0|
|Ask||22.50 x 0|
|Day's Range||21.55 - 23.00|
|52 Week Range||15.00 - 32.95|
|Beta (5Y Monthly)||1.35|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 07, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||77.50|
The shareholders in Saniona AB, Reg. No. 556962-5345, are hereby invited to attend the annual shareholders’ meeting (Sw. As a precautionary measure to reduce the risk of spreading the coronavirus, the board of directors of Saniona AB (“Saniona”) has decided to keep planned speeches at the shareholders’ meeting to a minimum and that no refreshments will be served. Participation at the shareholders’ meeting by members of the board of directors and management as well as the number of non-shareholders present at the shareholders’ meeting will be limited in an effort to keep the shareholders’ meeting brief and efficient, and thereby minimizing the risk of spreading the coronavirus.
PRESS RELEASE March 31, 2020 Saniona AB (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced that the board of directors.
Saniona (SANION.ST), a clinical stage biopharmaceutical company focused on rare diseases of the central nervous system, today announced a new research collaboration with Boehringer Ingelheim in schizophrenia. Saniona may receive up to €76.5 million in milestone payments as well as royalties on worldwide net sales of resulting products under the collaboration.
Saniona (SANION.ST), a clinical stage biopharmaceutical company focused on rare diseases of the central nervous system, today announced the appointment of Anita Milland as interim Chief Financial Officer and Head of Investor Relations effective immediately following the departure of Saniona Chief Financial Officer and co-founder Thomas Feldthus. As part of Saniona’s strategic transformation and expansion in the US, Jorgen Drejer, Ph.D., Chief Scientific Officer and co-founder will assume the role of Deputy Chief Executive Officer, which was previously held by Mr. Feldthus.
Saniona (SANION.ST), a clinical stage biopharmaceutical company focused on rare diseases of the central nervous system, today announces the last patient has completed the last visit in the six-month, placebo-controlled section of a Phase 2a study of Tesomet in hypothalamic obesity (HO). A total of 18 patients, of the original 21 who started the trial, have now continued into the open-label extension part of the study. The placebo-controlled part of the study remains on track to report top-line results in Q2 2020.
Saniona AB's rights issue of units has been registered with the Swedish Companies Registration Office. Euroclear's record date for conversion from BTU to warrants is March 19th, 2020. The new warrants are expected to be distributed to the respective shareholder’s VP account/depot on March 23rd, 2020.
On March 2, 2020 Saniona AB´s rights issue of free-of-payment units, consisting of 3,042,672 warrants of three separate series (TO 1, TO 2, TO 3) has ended. The rights issue was oversubscribed and approximately 95,77 percent of the rights issue was subscribed for by exercise of unit rights (subscription rights for units allotted to shareholders).A total of 1,014,224 units are issued through the rights issue consisting of 1,014,224 warrants of series TO 1, 1,014,224 warrants of series TO 2 and 1,014,224 warrants of series TO 3.
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, AUSTRALIA, JAPAN, CANADA, NEW ZEALAND, SOUTH AFRICA, HONG KONG, SWITZERLAND, SINGAPORE OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE. Saniona AB (publ) (”Saniona”) has prepared a supplementary prospectus, in addition to the prospectus relating to Saniona’s current rights issue of units, which was published on February 14, 2020 and which has been approved and registered by the Swedish Financial Supervisory Authority. The supplementary prospectus is available on Sanionas website www.saniona.com/se and on Sedermera Fondkommissions website www.sedermera.se.
Saniona (SANION.ST), a clinical stage biotech company focused on rare diseases of the Central Nervous System, today announces that co-founder and Chief Financial Officer Thomas Feldthus will be leaving the company. As part of its strategic transformation Saniona has initiated the search for a new CFO, who will be based in the U.S. along with CEO Rami Levin. Thomas Feldthus, who is one of the co-founders of Saniona, will continue as CFO for an interim period to ensure a smooth transition and transfer of responsibilities to the new CFO.
The prospectus relating to the rights issue of units that Saniona AB (“Saniona or the Company”) announced on January 10, 2020 has today been approved and registered by the Swedish Financial Supervisory Authority and is now available on Saniona’s website, www.saniona.com, together with other information related to the rights issue. The prospectus will also be available on Sedermera Fondkommissions website, www.sedermera.se and on the Swedish Financial Supervisory Authority website, www.fi.se. The subscription period for the rights issue commences on Monday, 17 February 2020 and proceeds up to and including 2 March 2020.
Today, on February 7, 2020, an extraordinary general meeting was held in Saniona AB. The extraordinary general meeting resolved to approve the board of directors’ resolution of January 10, 2020, on a directed issue of a maximum of 465,518 units consisting of warrants. With deviation from the shareholders' preferential rights, the units may only be subscribed for by Formue Nord Fokus A/S and Formue Nord Markedsneutral A/S, whereby 102,414 units shall be subscribed for by Formue Nord Fokus A/S and 363,104 units shall be subscribed for by Formue Nord Markedsneutral A/S. The reason for the deviation from the shareholders' preferential rights is that the warrants are issued as part of the financing structure which was published by the company on January 10, 2020.
PRESS RELEASE February 7, 2020 Financial highlights Jan – Dec 2019 (Jan – Dec 2018) Net revenues were SEK 2.7 M (54.9 M)EBIT was SEK -103.9 M (-54.2 M)Net profit/loss was.
During January, the registered number of shares and votes in Saniona AB (publ) (“Saniona”) has increased due to the directed issue of shares resolved by the board of directors on January 10, 2020. This information is such information as Saniona AB (publ) is obliged to make public pursuant to the Swedish Financial Instruments Trading Act. The Company has five programs in clinical development.
The shareholders in Saniona AB, Reg. No. 556962-5345, are hereby invited to attend the extraordinary general meeting (Sw. Such temporary re-registration of ownership must be implemented no later than as of Saturday 1 February 2020.
PRESS RELEASE NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION IN WHICH.
Saniona (SANION.ST), a clinical stage biotech company focused on rare diseases relating to eating disorders and the central nervous system (CNS), today announces that it has appointed the highly experienced pharmaceutical industry executive Rami Levin as Chief Executive Officer to oversee its transition to a fully-fledged biopharmaceutical company with focus on rare diseases.
Saniona (SANION.ST), a clinical stage biotech company focused on eating disorders and CNS, today announced that its partner Medix has submitted a new drug application to the Mexican food and drug administration (Comisión Federal para la Protección contra Riesgos Sanitarios, COFEPRIS) for approval of tesofensine for the treatment of patients with obesity. Saniona’s priority is to develop and gain market approval for Tesomet in the U.S. and Europe for Prader-Willi syndrome (PWS) and hypothalamic obesity, two rare eating disorders.
Saniona AB (publ) (STO:SANION) shareholders have seen the share price descend 10% over the month. But that scarcely...
The Annual General Meeting on May 29, 2019, resolved that a Nomination Committee shall be appointed before coming election and remuneration. The Nomination Committee shall comprise three members, which should be representative for the two largest shareholders as of last September, together with the Chairman of the Board of Directors. On September 30, 2019, the two largest shareholders, which desired to appoint a representative to the Nomination Committee, were Jørgen Drejer and Thomas Feldthus.
PRESS RELEASE November 13, 2019 Financial highlights Jan – Sep 2019 (Jan – Sep 2018) Net revenues were SEK 2.7 M (52.7 M)EBIT was SEK -75.8 M (-19.9 M)Net.
Saniona (SANION.ST), a clinical stage biotech company focused on eating disorders and CNS, today announces that it has recruited the last patient in the Phase 2a clinical study for Tesomet in hypothalamic obesity. Saniona expects to report top line results from the double-blind part of the study in Q2 2020. “Following the positive Phase 2a data recently reported in Prader-Willi syndrome, we are pleased with the Phase 2a progress in our second rare eating disorder, hypothalamic obesity.
If you're interested in Saniona AB (publ) (STO:SANION), then you might want to consider its beta (a measure of share...